Leiden University Scholarly Publications

Your Search

Enabled Filters

  • (-) = Kavanaugh, A.

Refine Results

Resource Type

Availability

Creation Date

Show more

Faculty

Collection

Topic

Show more

Author

Show more

Language

Search results

  • RSS Feed
(1 - 20 of 80)

Pages

Assessing structural damage progression in psoriatic arthritis and its role as an outcome in research
Heijde, D. van der; Gladman, D.D.; Kavanaugh, A.; Mease, P.J. 2020
Assessing structural damage progression in psoriatic arthritis and its role as an outcome in research
Article / Letter to editor
open access
Psoriatic arthritis (PsA) is an immune-mediated, clinically heterogeneous disease characterized by arthritis, enthesitis, dactylitis, spondylitis, and psoriasis of the skin and nails. Persistent... Show morePsoriatic arthritis (PsA) is an immune-mediated, clinically heterogeneous disease characterized by arthritis, enthesitis, dactylitis, spondylitis, and psoriasis of the skin and nails. Persistent articular inflammation in patients with PsA can lead to structural damage, which can result in reduced physical function and quality of life. Structural damage can occur rapidly, and irreversible joint damage may be observed if patients are not treated promptly and appropriately. Therefore, evaluating therapeutic agents for their ability to inhibit structural progression has become increasingly important, with radiographic progression becoming a key efficacy outcome in clinical trials in PsA. Here, we review how structural damage and progression are assessed in clinical trials and the use of radiographic progression as a study outcome. We also discuss possible limitations in the current assessment of radiographic progression as well as areas of research that may improve the assessment of structural damage in clinical trials of PsA. Show less
Radiographic Progression According to Baseline C-reactive Protein Levels and Other Risk Factors in Psoriatic Arthritis Treated with Tofacitinib or Adalimumab
Heijde, D. van der; Gladman, D.D.; FitzGerald, O.; Kavanaugh, A.; Graham, D.; Wang, C.S.; Fallon, L. 2019
Radiographic Progression According to Baseline C-reactive Protein Levels and Other Risk Factors in Psoriatic Arthritis Treated with Tofacitinib or Adalimumab
Article / Letter to editor
metadata only
Long-Term Radiographic and Patient-Reported Outcomes in Patients with Rheumatoid Arthritis Treated with Tofacitinib: ORAL Start and ORAL Scan Post-hoc Analyses
Strand, V.; Kavanaugh, A.; Kivitz, A.J.; Heijde, D. van der; Kwok, K.; Akylbekova, E.; ... ; Smolen, J.S. 2018
Long-Term Radiographic and Patient-Reported Outcomes in Patients with Rheumatoid Arthritis Treated with Tofacitinib: ORAL Start and ORAL Scan Post-hoc Analyses
Article / Letter to editor
open access
Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force
Smolen, J.S.; Schoels, M.; Braun, J.; Dougados, M.; FitzGerald, O.; Gladman, D.D.; ... ; Heijde, D. van der 2018
Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force
Other
open access
Tofacitinib Treatment in Patients with Psoriatic Arthritis and Rates of Radiologic Progression According to Baseline CRP Levels: Results from a Phase 3 Clinical Study
Heijde, D. van der; Gladman, D.D.; FitzGerald, O.; Kavanaugh, A.; Graham, D.; Wang, C.S.; Fallon, L. 2017
Tofacitinib Treatment in Patients with Psoriatic Arthritis and Rates of Radiologic Progression According to Baseline CRP Levels: Results from a Phase 3 Clinical Study
Article / Letter to editor
metadata only
New GRAPPA and EULAR recommendations for the management of psoriatic arthritis
Coates, L.C.; Gossec, L.; Ramiro, S.; Mease, P.; Heijde, D. van der; Smolen, J.S.; ... ; Kavanaugh, A. 2017
New GRAPPA and EULAR recommendations for the management of psoriatic arthritis
Article / Letter to editor
metadata only
EFFECT OF STARTING DOSE OF BARICITINIB IN ACHIEVING SUSTAINED LOW DISEASE ACTIVITY
Curtis, J.R.; Kavanaugh, A.; Heijde, D. van der; Muram, D.; Alam, J.; Beattie, S.; Smolen, J.S. 2017
EFFECT OF STARTING DOSE OF BARICITINIB IN ACHIEVING SUSTAINED LOW DISEASE ACTIVITY
Article / Letter to editor
metadata only
EFFECT OF BASELINE DISEASE ACTIVITY ON ACHIEVING SUSTAINED LOW DISEASE ACTIVITY IN BARICITINIB PHASE 3 STUDIES
Curtis, J.R.; Kavanaugh, A.; Heijde, D. van der; Muram, D.; Alam, J.; Smolen, J.S. 2017
EFFECT OF BASELINE DISEASE ACTIVITY ON ACHIEVING SUSTAINED LOW DISEASE ACTIVITY IN BARICITINIB PHASE 3 STUDIES
Article / Letter to editor
metadata only
Management of psoriatic arthritis in 2016: a comparison of EULAR and GRAPPA recommendations
Gossec, L.; Coates, L.C.; Wit, M. de; Kavanaugh, A.; Ramiro, S.; Mease, P.J.; ... ; Smolen, J.S. 2016
Management of psoriatic arthritis in 2016: a comparison of EULAR and GRAPPA recommendations
Article / Letter to editor
metadata only
LONG-TERM IMPROVEMENTS IN WORKPLACE AND HOUSEHOLD PRODUCTIVITY AND SOCIAL PARTICIPATION OVER 4 YEARS OF CERTOLIZUMAB PEGOL TREATMENT IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS, INCLUDING ANKYLOSING SPONDYLITIS AND NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS
Heijde, D. van der; Braun, J.; Rudwaleit, M.; Landewe, R.; Purcaru, O.; Kavanaugh, A. 2016
LONG-TERM IMPROVEMENTS IN WORKPLACE AND HOUSEHOLD PRODUCTIVITY AND SOCIAL PARTICIPATION OVER 4 YEARS OF CERTOLIZUMAB PEGOL TREATMENT IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS, INCLUDING ANKYLOSING SPONDYLITIS AND NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS
Article / Letter to editor
metadata only
LONG-TERM IMPROVEMENTS IN WORKPLACE AND HOUSEHOLD PRODUCTIVITY AND SOCIAL PARTICIPATION OVER 4 YEARS OF CERTOLIZUMAB PEGOL TREATMENT IN PATIENTS WITH PSORIATIC ARTHRITIS, WITH AND WITHOUT PRIOR ANTI-TNF EXPOSURE
Kavanaugh, A.; Gladman, D.; Heijde, D. van der; Purcaru, O.; Mease, P.J. 2016
LONG-TERM IMPROVEMENTS IN WORKPLACE AND HOUSEHOLD PRODUCTIVITY AND SOCIAL PARTICIPATION OVER 4 YEARS OF CERTOLIZUMAB PEGOL TREATMENT IN PATIENTS WITH PSORIATIC ARTHRITIS, WITH AND WITHOUT PRIOR ANTI-TNF EXPOSURE
Article / Letter to editor
metadata only
EFFICACY AND SAFETY OF SARILUMAB PLUS MTX IN SUBGROUPS OF PATIENTS WITH RHEUMATOID ARTHRITIS IN A PHASE 3 STUDY
Kavanaugh, A.; Kivitz, A.J.; Miranda, P.C.; Fiore, S.; Fay, J.; Fan, C.P.; ... ; Huizinga, T.W.J. 2016
EFFICACY AND SAFETY OF SARILUMAB PLUS MTX IN SUBGROUPS OF PATIENTS WITH RHEUMATOID ARTHRITIS IN A PHASE 3 STUDY
Article / Letter to editor
metadata only
Radiographic Progression of Patients With Psoriatic Arthritis Who Achieve Minimal Disease Activity in Response to Golimumab Therapy: Results Through 5 Years of a Randomized, Placebo-Controlled Study
Kavanaugh, A.; Heijde, D. van der; Beutler, A.; Gladman, D.; Mease, P.; Krueger, G.G.; ... ; Xu, S. 2016
Radiographic Progression of Patients With Psoriatic Arthritis Who Achieve Minimal Disease Activity in Response to Golimumab Therapy: Results Through 5 Years of a Randomized, Placebo-Controlled Study
Article / Letter to editor
metadata only
CLINICAL RESPONSES IN JOINT AND SKIN OUTCOMES AND PATIENT-REPORTED OUTCOMES ARE ASSOCIATED WITH INCREASED PRODUCTIVITY IN THE WORKPLACE AND AT HOME IN PSORIATIC ARTHRITIS PATIENTS TREATED WITH CERTOLIZUMAB PEGOL
Kavanaugh, A.; Cladman, D.; Heijde, D. van der; Purcaru, O.; Mease, P.J. 2015
CLINICAL RESPONSES IN JOINT AND SKIN OUTCOMES AND PATIENT-REPORTED OUTCOMES ARE ASSOCIATED WITH INCREASED PRODUCTIVITY IN THE WORKPLACE AND AT HOME IN PSORIATIC ARTHRITIS PATIENTS TREATED WITH CERTOLIZUMAB PEGOL
Article / Letter to editor
metadata only
Clinical Responses in Joint and Skin Outcomes and Patient-Reported Outcomes Are Associated with Increased Productivity in the Workplace and at Home in Psoriatic Arthritis Patients Treated with Certolizumab Pegol
Kavanaugh, A.; Gladman, D.; Heijde, D. van der; Purcaru, O.; Mease, P.J. 2015
Clinical Responses in Joint and Skin Outcomes and Patient-Reported Outcomes Are Associated with Increased Productivity in the Workplace and at Home in Psoriatic Arthritis Patients Treated with Certolizumab Pegol
Article / Letter to editor
metadata only
Secukinumab improves active psoriatic arthritis and inhibits radiographic progression: Results of a phase 3 randomized, multicenter, double-blind, placebo-controlled study
Mease, P.; McInnes, I.B.; Kirkham, B.; Kavanaugh, A.; Rahman, P.; Heijde, D. van der; ... ; Mpofu, S. 2015
Secukinumab improves active psoriatic arthritis and inhibits radiographic progression: Results of a phase 3 randomized, multicenter, double-blind, placebo-controlled study
Article / Letter to editor
metadata only
Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis
Mease, P.J.; McInnes, I.B.; Kirkham, B.; Kavanaugh, A.; Rahman, P.; Heijde, D. van der; ... ; FUTURE 1 Study Grp 2015
Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis
Article / Letter to editor
metadata only
Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial
McInnes, I.B.; Mease, P.J.; Kirkham, B.; Kavanaugh, A.; Ritchlin, C.T.; Rahman, P.; ... ; FUTURE 2 Study Grp 2015
Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial
Article / Letter to editor
metadata only
Certolizumab pegol plus methotrexate 5-year results from the rheumatoid arthritis prevention of structural damage (RAPID) 2 randomized controlled trial and long-term extension in rheumatoid arthritis patients
Smolen, J.S.; Vollenhoven, R. van; Kavanaugh, A.; Strand, V.; Vencovsky, J.; Schiff, M.; ... ; Heijde, D. van der 2015
Certolizumab pegol plus methotrexate 5-year results from the rheumatoid arthritis prevention of structural damage (RAPID) 2 randomized controlled trial and long-term extension in rheumatoid arthritis patients
Article / Letter to editor
metadata only
SECUKINUMAB, A HUMAN ANTI-INTERLEUKIN-17A MONOCLONAL ANTIBODY, IMPROVES ACTIVE PSORIATIC ARTHRITIS AND INHIBITS RADIOGRAPHIC PROGRESSION: EFFICACY AND SAFETY DATA FROM A PHASE 3 RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY
Nash, P.; Mease, P.; McInnes, I.; Kirkham, B.; Kavanaugh, A.; Rahman, P.; ... ; Mpofu, S. 2015
SECUKINUMAB, A HUMAN ANTI-INTERLEUKIN-17A MONOCLONAL ANTIBODY, IMPROVES ACTIVE PSORIATIC ARTHRITIS AND INHIBITS RADIOGRAPHIC PROGRESSION: EFFICACY AND SAFETY DATA FROM A PHASE 3 RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY
Article / Letter to editor
metadata only

Pages